Blueprint Medicines Corp. (NASDAQ:BPMC) shares saw strong trading volume on Tuesday . 170,715 shares changed hands during mid-day trading, an increase of 14% from the previous session’s volume of 149,920 shares.The stock last traded at $26.53 and had previously closed at $25.01.

A number of equities analysts recently commented on the company. TheStreet upgraded Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. Wedbush restated an “outperform” rating and issued a $41.00 price objective on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. Canaccord Genuity assumed coverage on Blueprint Medicines Corp. in a report on Friday, August 5th. They issued a “buy” rating and a $26.00 price objective on the stock. Zacks Investment Research upgraded Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a report on Thursday, August 11th. Finally, Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $29.43.

The stock has a 50 day moving average of $21.83 and a 200 day moving average of $18.65. The company’s market cap is $716.89 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last released its earnings results on Tuesday, August 9th. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.03. The firm earned $7.07 million during the quarter, compared to the consensus estimate of $4.41 million. The company’s revenue was up 163.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.81) EPS. Analysts expect that Blueprint Medicines Corp. will post ($2.92) EPS for the current year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $22.86, for a total value of $388,620.00. Following the sale, the chief executive officer now owns 76,494 shares in the company, valued at approximately $1,748,652.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

An institutional investor recently raised its position in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC boosted its stake in shares of Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned about 2.73% of Blueprint Medicines Corp. worth $19,500,000 at the end of the most recent quarter.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.